1
|
Tsabouri S, Ntritsos G, Koskeridis F, Evangelou E, Olsson P, Kostikas K. Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis. Rhinology 2021; 59:501-510. [PMID: 34714895 DOI: 10.4193/rhin21.159] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Allergic rhinitis (AR), an IgE mediated inflammatory disease, significantly impacts quality of life of a considerable proportion of the general population. Omalizumab, a humanized monoclonal antibody against IgE, has been evaluated for both seasonal and perennial AR. We aimed to assess the efficacy and safety of omalizumab in randomized controlled trials (RCTs) in inadequately controlled AR. METHODS We conducted a systematic literature search of RCTs evaluating the safety and efficacy of omalizumab in AR. We synthesized evidence for clinical improvement of AR symptoms, quality of life, reduction of the use of rescue medication, and adverse events. RESULTS The systematic search returned 289 articles, of which 12 RCTs were eligible for data extraction and meta-analysis. Omalizumab reduced the Daily Nasal Symptom Severity Score (DNSSS) by a summary standardized mean difference of -0.41 points with large heterogeneity; omalizumab significantly reduced the DNSSS both in the 3 cedar pollen-induced AR trials by -0.97 points and to a lower extent in the remaining five non-cedar trials by -0.19 points. Omalizumab also improved the Daily Ocular Symptom Severity Score (DOSSS) by a summary standardized mean difference of -0.30 points with large heterogeneity; the Rhino-conjunctivitis Quality of Life Questionnaire by a summary standardized mean difference of -0.45 points with no heterogeneity and the mean daily consumption of rescue antihistamines by a summary standardized mean difference of -0.21 with large heterogeneity. No statistically significant difference in the occurrence of adverse events was observed between omalizumab and placebo. CONCLUSION Our findings further support the efficacy and safety of omalizumab in the management of patients with allergic rhinitis inadequately controlled with a conventional treatment.
Collapse
Affiliation(s)
- S Tsabouri
- University of Ioannina, Medical School, Ioannina, Greece
| | - G Ntritsos
- University of Ioannina, Medical School, Ioannina, Greece
| | - F Koskeridis
- University of Ioannina, Medical School, Ioannina, Greece
| | - E Evangelou
- University of Ioannina, Medical School, Ioannina, Greece
| | | | - K Kostikas
- University of Ioannina, Medical School, Ioannina, Greece
| |
Collapse
|
2
|
Ntritsos G, Dimou N, Kypreou K, Stefanaki I, Loizidou MA, Hadjisavvas A, Kyriacou K, MacGregor S, Law MH, Iles MM, Stratigos AJ, Evangelou E. Assessment of melanoma candidate genes in a meta-analysis of 16 534 melanoma cases. J Eur Acad Dermatol Venereol 2019; 33:e369-e370. [PMID: 31071243 DOI: 10.1111/jdv.15662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- G Ntritsos
- Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
| | - N Dimou
- Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
| | - K Kypreou
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
| | - I Stefanaki
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
| | - M A Loizidou
- Department of EM/Molecular Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
| | - A Hadjisavvas
- Department of EM/Molecular Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.,Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
| | - K Kyriacou
- Department of EM/Molecular Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.,Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
| | | | - S MacGregor
- Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - M H Law
- Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - M M Iles
- Leeds Institute for Data Analytics, School of Medicine, University of Leeds, Leeds, UK
| | - A J Stratigos
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
| | - E Evangelou
- Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.,Department of Epidemiology and Biostatistics, Imperial College London, St Mary's Campus, London, UK
| |
Collapse
|
3
|
Masouri S, Stefanaki I, Kypreou K, Kodela E, Bethimoutis G, Ntritsos G, Evangelou E, Stratigos A, Antoniou C. Replication of risk variants for psoriasis in a Southern European case–control study: correlation with clinical subphenotypes. Br J Dermatol 2015; 173:552-4. [DOI: 10.1111/bjd.13625] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- S. Masouri
- Department of Dermatology Andreas Syggros Hospital University of Athens Ionos Dragoumi 5 16121 Athens Greece
| | - I. Stefanaki
- Department of Dermatology Andreas Syggros Hospital University of Athens Ionos Dragoumi 5 16121 Athens Greece
| | - K.P. Kypreou
- Department of Dermatology Andreas Syggros Hospital University of Athens Ionos Dragoumi 5 16121 Athens Greece
| | - E. Kodela
- Department of Dermatology Andreas Syggros Hospital University of Athens Ionos Dragoumi 5 16121 Athens Greece
| | - G. Bethimoutis
- Department of Dermatology Andreas Syggros Hospital University of Athens Ionos Dragoumi 5 16121 Athens Greece
| | - G. Ntritsos
- Department of Hygiene and Epidemiology University of Ioannina Medical School Ioannina Greece
| | - E. Evangelou
- Department of Hygiene and Epidemiology University of Ioannina Medical School Ioannina Greece
- Department of Epidemiology and Biostatistics School of Public Health Imperial College London London U.K
| | - A.J. Stratigos
- Department of Dermatology Andreas Syggros Hospital University of Athens Ionos Dragoumi 5 16121 Athens Greece
| | - C. Antoniou
- Department of Dermatology Andreas Syggros Hospital University of Athens Ionos Dragoumi 5 16121 Athens Greece
| |
Collapse
|